Furthermore, MK-2206 did not significantly alter the efficacy of doxorubicin and paclitaxel, which are substrates for the ABCB1 transporter, in the ABCB1-overexpressing cancer cells, KB-C2 and SW620/Ad300. Here, ABCB1 is linked to cancer.